Skip to content

PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention

Pressure Controlled Intermittent Coronary Sinus Occlusion in Patients With ST Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: Safety and Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01493037
Acronym
pRAMSES
Enrollment
30
Registered
2011-12-15
Start date
2011-12-31
Completion date
Unknown
Last updated
2014-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Elevation (STEMI) Myocardial Infarction

Keywords

STEMI, PICSO, Coronary Sinus, Involving Left Anterior Descending Coronary Artery

Brief summary

A prospective multi-center study in which patients with an acute heart attack (in the left anterior descending artery) with ECG changes (ST segment elevation) receive angioplasty followed by stent placement and 90 minutes of PICSO treatment. This is a proof of concept study designed to document the safety and feasibility of the Pressure Controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse system.

Interventions

DEVICEPICSO (Pressure-controlled Intermittent Coronary Occlusion

The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.

Sponsors

Miracor Medical SA
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* First time anterior STEMI defined by the following: * Symptoms of myocardial ischemia \> 30 minutes and \< 12 hours * ST-segment elevation \> 1mm (\> 0.1 mV) in two contiguous precordial leads in the anterior territory on a 12-lead ECG * Uncomplicated PCI of a LAD culprit lesion (defined as angioplasty followed by stent placement or direct stenting without the occurrence of an adverse event(s) that would preclude further study participation, such as major bleeding, perforation, hypotension, pulmonary edema or instability that in the judgement of the investigator preclude participation in the trial)

Exclusion criteria

* Younger than 18 years of age * Hospitalization with a primary diagnosis of acute myocardial infarction (AMI) previously or has evidence of previous Q-wave infarct * Left main coronary artery culprit lesion * Additional stenosis in the LAD for which PCI or CABG is likely to be needed in the next 6 months and which is not treated during the index procedure * Cardiogenic shock (systolic blood pressure ≤90 mmHg in spite of conservative measures) or pulmonary edema (O2 saturation \<90% by pulse oximetry and the presence of rales or crackles) * Cardiac arrest requiring chest compression or resuscitation * Anatomical complications limit capacity to place PICSO Impulse device or achieve stable catheter placement or occlude coronary sinus * Known renal disease (GFR \< 30 mL/min/1.73m2) or dialysis * History of stroke, TIA or reversible ischemic neurological disease within last 6 months * Left bundle branch block * Known contra-indication for magnetic resonance imaging (Metallic implant precluding MRI, claustrophobia, obesity precluding MRI, etc.) * Presence of any lead in the coronary sinus * Active or treated malignancies in the last 12 months * Previous coronary artery bypass graft surgery * Known severe anemia (Hgb \< 10 g/dL or \< 6.2 mmol/L) * Known platelet count \< 100,000, known coagulopathy or bleeding diathesis, or unwilling to accept transfusions * Participation in another ongoing clinical study * Women of child-bearing age * Non-cardiac comorbidities and life expectancy \< 1 year * Legal incompetence * A condition that, in the opinion of the Investigator, precludes participation, including compliance with all follow-up procedures * No dependents neither to the sponsor nor to the investigator

Design outcomes

Primary

MeasureTime frameDescription
Successful delivery of PICSO treatment90 minutesAssessment of the feasibiity of PICSO in STEMI patients defined as the successful elivery of the PICSO catheter and the successful administration of PICSO treatment for 90 minutes

Secondary

MeasureTime frameDescription
Assessment of left ventricular function4 monthsLeft ventricular function assessed by echocardiography between 2-5 days after primary PCI and at 120 days
Assessment of microvascular perfusion4 monthsMicrovascular perfusion assessed by cardiac MRI between 2-5 days after primary PCI and at 120 days
MRI measurement of infarct size4 monthsInfarct size assessed by cardiac MRI between 2-5 days post primary PCI and again at 120 days follow up
Measurement of ST segment time curve area3 hoursST segment time curve area for the first 3 hours on 24 hour continuous 12 lead ECG Holter monitor recording.
Number of adverse events6 monthsSafety endpoints recorded are Major Adverse Cardiac Events (MACE), Major Adverse Cardiac and Cerebrovascular Events (MACCE), net adverse clinical events (MACE and bleeding), Serious and non serious Adverse Device Events ((S)ADE) rates
Resolution of ST-segment elevation24 hoursOccurrence of complete resolution of ST-segment elevation 30, 60, 90 and 120 minutes after last contrast injection prior to PICSO placement procedure on 24 hour continuous 12 lead ECG Holter monitor recording

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026